Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
MRI
SWI
glioblastoma
Journal
Journal of neuroimaging : official journal of the American Society of Neuroimaging
ISSN: 1552-6569
Titre abrégé: J Neuroimaging
Pays: United States
ID NLM: 9102705
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
02
04
2019
accepted:
09
05
2019
pubmed:
22
5
2019
medline:
20
6
2020
entrez:
22
5
2019
Statut:
ppublish
Résumé
Susceptibility-weighted magnetic resonance imaging (SWI) yields information regarding tumor biology (e.g., hemorrhage) of growing gliomas. SWI changes can also be observed as a consequence of treatment, for example radiation therapy. The aim of our study was to investigate how susceptibility changes occur during the time course after completion of standard treatment in newly diagnosed glioblastoma (GBM). Eighteen GBM patients were retrospectively analyzed. After completion of therapy, imaging was performed every 3 months. MRI was analyzed at the following time points: after the third and sixth cycle of adjuvant temozolomide chemotherapy, thereafter in 3 month intervals and at recurrence. The number of SWI positive tumor pixels was quantified and compared with progression as defined by the RANO criteria on T2- and contrast-enhanced T1-weighted MRI sequences (T1-CE). The MRI interval between completion of the sixth chemotherapy cycle and last MRI before progression was 390 ± 292 days. Between the last MRI before progression and at progression a significant increase in SWI positive tumor pixels was observed (P = .012), whereas tumor size remained unchanged (RANO T2: P = .385; RANO T1-CE: P = .165). The number of SWI positive pixels remained unchanged between last MRI before progression until progression (P = .149), whereas RANO T2 and T1-CE showed tumor progression (interval 128 ± 69 days). SWI positive pixel count increases significantly prior to changes in tumor size (RANO). Our findings may be explained by microbleeds compatible with stimulation of angiogenesis and possibly serve as an early biomarker of tumor progression.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Susceptibility-weighted magnetic resonance imaging (SWI) yields information regarding tumor biology (e.g., hemorrhage) of growing gliomas. SWI changes can also be observed as a consequence of treatment, for example radiation therapy. The aim of our study was to investigate how susceptibility changes occur during the time course after completion of standard treatment in newly diagnosed glioblastoma (GBM).
METHODS
METHODS
Eighteen GBM patients were retrospectively analyzed. After completion of therapy, imaging was performed every 3 months. MRI was analyzed at the following time points: after the third and sixth cycle of adjuvant temozolomide chemotherapy, thereafter in 3 month intervals and at recurrence. The number of SWI positive tumor pixels was quantified and compared with progression as defined by the RANO criteria on T2- and contrast-enhanced T1-weighted MRI sequences (T1-CE).
RESULTS
RESULTS
The MRI interval between completion of the sixth chemotherapy cycle and last MRI before progression was 390 ± 292 days. Between the last MRI before progression and at progression a significant increase in SWI positive tumor pixels was observed (P = .012), whereas tumor size remained unchanged (RANO T2: P = .385; RANO T1-CE: P = .165). The number of SWI positive pixels remained unchanged between last MRI before progression until progression (P = .149), whereas RANO T2 and T1-CE showed tumor progression (interval 128 ± 69 days).
CONCLUSIONS
CONCLUSIONS
SWI positive pixel count increases significantly prior to changes in tumor size (RANO). Our findings may be explained by microbleeds compatible with stimulation of angiogenesis and possibly serve as an early biomarker of tumor progression.
Substances chimiques
Antineoplastic Agents, Alkylating
0
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
645-649Informations de copyright
© 2019 by the American Society of Neuroimaging.
Références
Wen PY, Kesari S. 2008. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
Haacke EM, Xu Y, Cheng YC, et al. Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612-8.
Haacke EM, Mittal S, Wu Z, et al. Susceptibility weighted imaging: technical aspects and clinical applications: part 1. AJNR 2009;30:19-30.
Berberat J, Grobholz R, Boxheimer L, et al. Differentiation between calcification and hemorrhage in brain tumors using susceptibility-weighted imaging: a pilot study. AJR Am J Roetgenoel 2014;202:847-50.
Di Ieva A, Lam T, Alcaide-Leon P, et al. Magnetic resonance susceptibility weighted imaging in neurosurgery: current applications and future perspectives. J Neurosurg 2015;123:1463-75.
Mittal S, Wu Z, Neelavalli J, et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 2009;30:232-52.
Robinson RJ, Bhuta S. Susceptibility-weighted imaging of the brain: current utility and potential applications. J Neuroimaging 2011;21:e189-204.
Hsu CC, Watkins TW, Kwan GN, et al. Susceptibility-weighted imaging of glioma: update on current imaging status and future directions. J Neuroimaging 2016;26:383-90.
Sehgal V, Delproposto Z, Haddar D, et al. Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J Magn Reson Imaging 2006;24:41-51.
Reichenbach JR, Venkatesan R, Schillinger DJ, et al. Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology 1997;204:272-7.
Li C, Ai B, Li Y, et al. Susceptibility-weighted imaging in grading brain astrocytomas. Eur J Radiol 2010;75:e81-5.
Sedlacik J, Kutschbach C, Rauscher A, et al. Investigation of the influence of carbon dioxide concentrations on cerebral physiology by susceptibility-weighted magnetic resonance imaging (SWI). Neuroimage 2008;43:36-43.
Rauscher A, Sedlacik J, Barth M, et al. Non-invasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn Reson Med 2005;54:87-95.
Rauscher A, Sedlacik J, Fitzek C, et al. High resolution susceptibility weighted MR-imaging of brain tumors during the application of a gaseous agent. Rofo 2005;177:1065-9.
Lupo JM, Molinaro AM, Essock-Burns E, et al. The effect of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Neuro Oncol 2016;18:87-95.
Haacke EM, Xu Y, Cheng YC, et al. Susceptibility-weighted imaging (SWI). Magn Reson Med 2004;52:612-8.
Haacke EM, Mittal S, Wu Z, et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009;30:19-30.
Rauscher A, Sedlacik J, Barth M et al. Magnetic susceptibility-weighted MR phase imaging of the human brain. Am J Neuroradiol 2005;26:736-42.
White ML, Zhang Y, Yu F, et al. Post-operative perfusion and diffusion MR imaging and tumor progression in high-grade gliomas. PLoS One 2019;14:e0213905.
Price SJ, Jena R, Burnet NG, et al. Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol 2007;17:1675-84.
Berberat J, McNamara J, Remonda L, Bodis S, Rogers S. Diffusion tensor imaging for target volume definition in glioblastoma multiforme. Strahlenther Onkol 2014;190:939-43.
Wen PY, Norden AD, Drappatz J, et al. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep 2010;12:68-75.
Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453-61.
Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405-10.
Roelcke U, Boxheimer L, Fathi AR, et al. Cortical hemosiderin is associated with seizures in patients with newly diagnosed malignant brain tumors. J Neurooncol 2013;115:463-8.
Kondziolka D, Bernstein M, Resch L, et al. Significance of hemorrhage into brain tumors: clinicopathological study. J Neurosurg 1987;67:852-7.
Park MJ, Kim HS, Jahng GH, et al. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol 2009;30:1402-8.
Reichenbach JR, Schweser F, Serres B, et al. Quantitative susceptibility mapping: concepts and applications. Clin Neuroradiol 2015;25(Suppl. 2):225-30.
Watling CJ, Lee DH, Macdonald DR, et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994;12:1886-9.
Steens SCA, Steup-Beekman GM, Bosma G, et al. The effect of corticosteroid medication on quantitative MR parameters of the brain. Am J Neuroradiol 2005;26:2475-80.